Supporting the role of DNA demethylation in T-ALL survival, combination treatment with a TCA cycle inhibitor (CPI-613) and a TET1/2 inhibitor (Bobcat339) resulted in an additive effect in reducing the T-ALL burden. This evidence concerns the gene TET1 and acute lymphoblastic leukemia.